Interactions of buspirone with itraconazole and rifampicin: Effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone

Pharmacology and Toxicology

Volumn 84, Issue 2, 1999, Pages 94-97

  Kivistö, Kari T ^a   Lamberg, Tommi S ^a   Neuvonen, Pertti J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 PYRIMIDINYL)PIPERAZINE; BUSPIRONE; ITRACONAZOLE; RIFAMPICIN;

ANXIETY NEUROSIS; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032986347     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1999.tb00880.x     Document Type: Article

References (12)

1. Backman, J. T., K. T. Kivistö, K. T. Olkkola & P. J. Neuvonen: The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur. J. Clin. Pharmacol. 1998, 54, 53-58.
2. 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine. Brit. J. Clin. Pharmacol. 1995, 39, 243-249.
3. 2-adrenoceptors by 1-(- pyrimidinyl)-piperazine (PmP) in vivo and its relation to the activity of buspirone. Eur. J. Pharmacol. 1988, 147, 343-350.
4. Buch, A. B., D. R. Van Harken, R. J. Seidehamel & R. H. Barbhaiya: A study of pharmacokinetic interaction between buspirone and alprazolam at steady state. J. Clin. Pharmacol. 1993, 33, 1104-1109.
5. Gaillard, Y., J. P. Gay-Montchamp & M. Ollagnier: Simultaneous screening and quantitation of alpidem, zolpidem, buspirone and benzodiazepines by dual-channel gas chromatography using electron-capture and nitrogen-phosphorus detection after solid-phase extraction. J. Chromatogr. 1993, 622, 197-208.
6. Gammans, R. E., R. F. Mayol & J. A. LaBudde: Metabolism and disposition of buspirone. Amer. J. Med. 1986, 80 (Suppl. 3B), 41-51.
7. Goa, K. L. & A. Ward: Buspirone: a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 1986, 32, 114-129.
8. Jajoo, H. K., R. F. Mayol, J. A. LaBudde & I. A. Blair: Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab. Dispos. 1989, 17, 634-640.
9. Kivistö, K. T., T. S. Lamberg, T. Kantola & P. J. Neuvonen: Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin. Pharmacol. Therap. 1997, 62, 348-354.
10. Lamberg, T. S., K. T. Kivistö & P. J. Neuvonen: Concentrations and effects of buspirone are considerably reduced by rifampicin. Brit. J. Clin. Pharmacol. 1998a, 45, 381-385.
11. Lamberg, T. S., K. T. Kivistö & P. J. Neuvonen: Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone. Clin. Pharmacol. Therap. 1998b, 63, 640-645.
12. 14C-buspirone HCl after intravenous and oral dosing in man. Clin. Pharmacol. Therap. 1985, 37, 210.